|Awarded On||August 19, 2020|
|Title||Developing Single-cell RNAseq- based Genetic Screens to Identify Novel Targets for Cancer Immunotherapy|
|Award Mechanism||High Impact/High Risk|
|Institution/Organization||University of Houston|
|Principal Investigator/Program Director||Weiyi Peng|
|Cancer Sites||All Sites|
*Pending contract negotiation
Immunotherapies including immune checkpoint blockade (ICB) and adoptive T cell therapy (ACT) have demonstrated durable responses in many patients with solid tumor malignancies. To maximize the clinical benefit of immunotherapy in cancer patients, it is important to identify molecular determinants in non-responders to cancer immunotherapy and understand how these molecular determinates govern antitumor immune responses. However, advancements in this field are hindered by a lack of high-throughput approaches to comprehensively evaluate the role of tumor intrinsic factors in controlling tumor sensitivity to the immune attack. To address this emerging challenge, we aim to develop a new genetic s...